
July 10, 2025 — Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, will be featured along with its PlaqueIQ image analysis software at the 20th Annual Meeting of the Society of Cardiovascular Computed Tomography (SCCT 2025), taking place July 17-20 at Palais des Congrès de Montréal.
Elucid CEO Kelly Huang, PhD, will participate in the Novel Technologies keynote session, on July 18. Kelly’s presentation, “Lesion, vessel, patient, population. Anatomy, physiology, morphology: A complete picture,” will detail the importance of plaque morphology quantification and classification at the lesion level and why morphology based on histology is the gold standard for plaque characterization.
Elucid also will host a breakfast symposium, “From Lesion Detail to the Patient: Getting the Entire Story with Anatomy, Physiology and Morphology,” on July 18. The session will feature two of the preeminent experts in preventative cardiology and CCTA-derived plaque morphology: Dr. Amir Ahmadi, associate professor of medicine and cardiology director, Inpatient Cardiology at Mount Sinai Fuster Heart at Morningside and Elucid lead scientific advisor, and Dr. Mark D. Berlacher, clinical cardiologist at The Christ Hospital. The session will provide a deep dive into several plaque cases using Elucid’s software and share how these findings influence treatment pathways. The program will also explore FFRCT features on an investigational basis.1
“The cases we will present at SCCT 2025 demonstrate the importance of moving beyond the vessel level to assess plaque at the lesion level,” said Dr. Berlacher. “Having detailed information about the amount and type of plaque at the lesion level, including lipid rich necrotic core, can help drive treatment decisions and help physicians get ahead of potentially deadly cardiac events.”
In addition to its participation in the SCCT 2025 program, Elucid will hold three dinner presentations and discussions on July 17, 18 and 19. The presentation, “CT-Guided Treatment of Coronary Artery Disease: A Step Toward Precision Medicine,” features Dr. Ahmadi, and will also include product demos.
PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology rather than subjective CCTA visual estimates. PlaqueIQ quantifies and classifies plaque morphology based on ground-truth histology, the gold standard for characterization of plaques. The software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk.
1. Elucid is pursuing an indication for FFRCT, derived from its plaque algorithm. This software is currently investigational and not cleared for use by the FDA